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Abstract
Aim. To test the effects of pre- and post-transplant clinical covariates on post-transplant health-related quality of life
(HRQOL) score profiles in liver transplant recipients. Material and methods. HRQOL was measured before and after
transplantation using the SF-36† Health Survey. Clinical data [diagnosis, model of end-stage liver disease (MELD) score,
post-transplant rejection and infection episodes], pre-transplant functional performance (FP), and demographics were
collected. Multivariate models for the eight SF-36 scales and two summary components were developed using multiple
regression. Discriminant analysis was used to test whether the score profiles differentiated among recipients with and
without hepatitis C virus (HCV) infection. Results. 104 adults reported pre- and post-transplant HRQOL. Time post-
transplant averaged 998 months (range 139). Scores on all SF-36 measures improved from pre- to post-transplant
(pB0.001), and 7 of 10 models were significant (pB0.05). After controlling for pre-transplant HRQOL and time post-
transplant, HCV infection had a negative effect on the role physical, bodily pain, and role emotional scales. History of a
rejection episode had a negative effect on the bodily pain and vitality scales. MELD scores ]18 had a positive effect on the
role physical scale. Pre-transplant FP and post-transplant infection episodes did not affect post-transplant HRQOL. HCV
infection had a significant effect on the SF-36 score profile (canonical correlation0.50; pB0.001). Conclusions. Pre-
transplant HCV infection, MELD score, and post-transplant rejection episodes have significant independent effects on
HRQOL after liver transplantation. Their specific effects vary among the individual SF-36 scales, and HRQOL score
profiles differ among HCV and HCV recipients.
Key Words: Graft rejection, HCV, liver transplantation, MELD, quality of life, score profile
Introduction
Longitudinal assessments of health-related quality of
life (HRQOL) after liver transplantation have in-
creased over the past decade. Previous research
demonstrated overall improvements in physical and
mental HRQOL after liver transplantation [15]. One
of the general conclusions gathered from these studies
has been that the HRQOL of most liver transplant
candidates starts below that of the general population.
However, they experience a notable improvement in
overall HRQOL during the first post-transplant year
that is sustained over the next several years. In
general, these improvements in global HRQOL are
driven by improvements in physical HRQOL with
smaller improvements in mental HRQOL. However,
there is a relationship between physical and mental
HRQOL  those patients with better post-transplant
physical HRQOL show greater improvements in
mental HRQOL [6]. Although these findings char-
acterize global improvements in HRQOL after liver
transplant, the collective influence of pre-transplant
factors and post-transplant clinical events on HRQOL
outcomes has not been well described.
Score profiles reflect the pattern of scores for a
collection of attributes, such as the eight individual
SF-36 scales. Profiles can be reported for individuals
or groups and are typically referenced to normative
data [7]. The profile approach to reporting the SF-36
scales has been described by the instrument’s devel-
opers [8], but this specific information is often not the
focus of clinical reports. In this article, we refer to
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‘‘HRQOL profiles’’ as summaries reflecting how the
eight HRQOL scales vary in relation to general
population norms as a function of both liver trans-
plantation (pre- and post-transplant profiles) and
pre-transplant HCV infection (HVC and HCV
recipient profiles).
A specific understanding of HRQOL profiles will
enable clinicians to recognize how clinical events
affect the pattern of HRQOL scores, with some scales
being within accepted limits of the general population
and others being below that of the general population.
For example, patients who were HCV before
transplant have been reported to have deteriorating
functional performance 3 years after liver transplant
in comparison to HCV recipients [9,10]. This effect
may be reflected in HCV patients having a unique
post-transplant HRQOL profile. Similarly, patients
who experience an acute rejection episode may have a
different HRQOL profile than those with an unre-
markable clinical course. The aims of this study are:
1) to model the effects of pre- and post-transplant
clinical covariates on individual post-transplant SF-36
scales and summary components; and 2) to evaluate
whether HRQOL profiles differ as a function of liver
transplantation and HCV.
Patients and methods
Patient and data acquisition
Beginning in January 2002, liver transplant candi-
dates and recipients were asked to complete a battery
of generic and specific HRQOL surveys at defined
pre- and post-transplant time-points using a rolling
enrolment system [11]. This IRB-approved protocol
involved the administration of these surveys and
integrating it with demographic and clinical data
from Vanderbilt Transplant Center and Vanderbilt
University Medical Center databases and records.
Patients included in this study were liver transplant
candidates listed after 1 January 2002 who received
liver transplants through 1 May 2006. If pre-trans-
plant HRQOL data were reported on more than one
occasion, the observation closest to the date of
transplant was selected as the baseline measure. In
instances where patients had reported HRQOL on
multiple occasions, post-transplant data from their
last self-report were used.
Demographic and clinical measures
Pre-transplant demographic measures, which were
collected for summary data reporting purposes, in-
cluded age, sex, and race. Pre-transplant clinical
measures included primary diagnosis and Model of
End-Stage Liver Disease (MELD) score. Whether a
candidate was infected with the hepatitis C virus
(HCV) was diagnosed prior to transplantation with
polymerase chain reaction amplification for detection
of HCV RNA, and this diagnosis was confirmed with
pathologic examination of the explanted liver after
surgery. Post-transplant clinical outcomes that were
hypothesized to have an effect on HRQOL were any
infectious episode(s) and any rejection episode(s) that
occurred prior to post-transplant HRQOL assess-
ment. A rejection episode was defined by a liver
biopsy confirming pathologic criteria for rejection; an
infectious episode was defined as a positive blood or
urine culture for bacterial, fungal, or viral pathogens
that required treatment.
HRQOL and functional performance status
The Medical Outcomes Study Short Form 36†
Health Survey (SF-36) was utilized for HRQOL
assessment. Karnofsky functional performance (FP)
status was also reported by transplant coordinators.
Data collection occurred at specific time-points, as
previously described: at initial evaluation, every
6 months while on the waiting list, and at 1 month,
3 months, six months, and annually post-transplant
[11].
The SF-36 was used to assess generic physical and
mental HRQOL. This 36-item questionnaire mea-
sures eight areas of functioning and well-being (role-
physical, bodily pain, physical functioning, general
health, vitality, social functioning, role-emotional, and
mental health). Physical and mental component
summary scales (PCS and MCS) are then computed
as weighted composites of the 8 scales. Scale scores
range from 0 to 100, with higher scores indicating a
better health state. The PCS and MCS are standar-
dized to the general population with a mean of 50 and
standard deviation of 10. Thus, 68% of the general
population are expected to score between 40 and
60 on the PCS and MCS scales [12].
Functional performance was evaluated by trans-
plant coordinators at the same time-points at which
patients completed the self-report surveys. Karnofsky
FP scores can range from 10 to 100 and are stratified
into 3 categories: 80 to 100 represents ability to carry
out normal work and activity (able); 50 to 70
represents ability to care for most personal needs
but with varying amounts of assistance and inability to
work (unable); and scores from 10 to 40 represent
patients who are unable to care for themselves and
need chronic care (disabled) [11,13].
Statistical methods
The five pre- and post-transplant clinical covariates
hypothesized to have potential effects on post-trans-
plant HRQOL scores were identified prior to analysis.
These included FP prior to transplant (encoded as
3 levels), HCV infection (positive or negative), and
MELD score (]18 or B18). Occurrences of any
episodes of rejection or infection after transplant (and
prior to HRQOL) were encoded as dichotomous
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covariates (yes/no). A statistical association between
each subject’s pre- and post-transplant HRQOL
scores was expected, so the relevant pre-transplant
HRQOL score was also included as a covariate in each
model. Additionally, since patients were surveyed at
varying times post-transplant, time post-transplant
(months) was included in all models. Effect sizes for
each covariate are reported as standardized regression
coefficients, which allow the reader to infer the
relative magnitude of individual effects. Standard
collinearity statistics were examined for each model.
The sample to covariate ratio (approximately 14:1)
was adequate for each model and the power to detect
a moderate (R2]0.15) overall effect for each model
was 86% at the 0.05 two-tailed alpha level.
Paired t-tests were used to determine the effect of
liver transplantation (pre- vs post-transplant) on all
SF-36 measures (the 8 scales and 2 summary
components). Multiple regression was used to de-
velop 10 multivariate models of the effects of each of
the consistent sets of covariates on the individual
HRQOL outcome measure. Models and effects with a
p-value of 50.05 were considered statistically sig-
nificant.
Score profiles for the 8 SF-36 scales were developed
and summarized pre- and post-transplant. The effect
of HCV infection on post-transplant score profiles
was tested using discriminant analysis and the degree
to which the discriminant function correctly classified
cases was examined. Summary data are presented
throughout as mean9standard deviation or percen-
tages. All analyses were conducted using SPSS,
version 15.0 (SPSS Inc, Chicago, IL, USA).
Results
One-hundred-and-four patients had pre- and post-
transplant HRQOL data. This represented 66% of
our non-veteran population over this time period.
This population was predominantly male (73%) and
an overwhelming majority were Caucasian (94%).
The mean age at time of transplantation was 5498
years, and the mean time post-transplant was 998
months (range 1 to 39 months). Indications for liver
transplantation included: 59% for non-cholestatic
cirrhosis (Hepatitis B, C, or Alcoholic Cirrhosis),
26% for metabolic liver disease, cryptogenic cirrhosis,
non-alcoholic steatohepatitis, or autoimmune hepati-
tis, 13% for cholestatic cirrhosis (primary biliary
cirrhosis and primary sclerosing cholangitis), and
2% for other indications (hepatocellular carcinoma
and hepatic epithelioid hemangoendothelioma). The
mean model of end-stage liver disease (MELD) score
was 2395, with a range from 12 to 40. Twenty-three
percent of patients had one or more episode of
rejection and 21% experienced one or more post-
transplant infection (Table I).
In general, patients’ HRQOL prior to liver
transplantation was well below that of the general
population (Table II). The greatest impairments were
seen in the physical function and general health scales,
which averaged 2 SD below the general population.
This sample of liver transplant recipients was unable
to function independently or work as classified by
their pre-transplant FP scores. However, significant










One or more rejection episodes 23%
One or more infectious episodes 21%
Values expressed as mean9standard deviation and percentages
where appropriate. NASHnon-alcoholic steatohepatitis,
MELDmodel of end-stage liver disease.
Table II. Pre- and post-transplant HRQOL scores.
Instruments General population Pre-transplant score Post-transplant score n p-valuea
SF-36 scales
1. Physical function 84923 35923 50927 104 B0.001
2. Role physical 81934 16931 34939 104 B0.001
3. Bodily pain 75924 43924 54927 101 B0.001
4. General health 72920 22917 55920 102 B0.001
5. Vitality 61921 20918 43926 103 B0.001
6. Social functioning 83923 43925 63930 107 B0.001
7. Role emotional 81933 42944 66942 101 B0.001
8. Mental health 75918 59922 71922 103 B0.001
SF-36 PCS 50910 2798 35911 94 B0.001
SF-36 MCS 50910 40911 49912 94 B0.001
Karnofsky functional performance status 59923 84912 104 B0.001
Values are expressed as means9SD.
aPre-transplant vs post-transplant within-subject comparison.
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improvement (pB0.001) was observed on all
10 HRQOL measures and FP scores from pre- to
post-transplant. Average post-transplant PCS and
MCS scores (Table II), and scores on six of the eight
individual SF-36 scales (Figure 1), approximated
those of the general United States population. The
pre-transplant profile demonstrates that patients were
functioning at levels substantively below the general
population on every scale except mental health. The
post-transplant profile shows these same patients
to be functioning within general population standards
on all scales except physical functioning and role
physical.
Seven out of 10 multivariate models of HRQOL
were statistically significant (pB0.05) (Table III).
These included the SF-36 physical component sum-
mary, physical functioning, role-physical, bodily pain,
social functioning, role emotional, and mental health
scales. Collinearity statistics were acceptable for every
covariate in all models (all tolerance values ]0.83).
Pre-transplant scores were positively associated with
post-transplant HRQOL in every model (all p50.10).
Time post-transplant had an inconsistent effect across
the models and was positively associated with
the PCS, role physical, and bodily pain scales
(all p50.10). After controlling for pre-transplant
HRQOL and time post-transplant, the collection of
pre- and post-transplant clinical covariates that were
statistically significant differed across the models. Pre-
transplant HCV infection had a statistically significant
negative effect on the post-transplant SF-36 role
physical (p0.018), bodily pain (p0.010), and
role emotional scales (p0.003), and a marginally
significant effect on social functioning (p0.099). A
history of one or more rejection episode had a
negative effect on the bodily pain (p0.007) and
vitality (p0.029) scales. Pre-transplant model of
end-stage liver disease (MELD) scores ]18 had a
significant positive effect on the role physical scale
(p0.052) and a marginal effect on bodily pain
(p0.072). The history of one or more infectious
episodes was not significantly associated with any
post-transplant HRQOL measure and pre-transplant
FP was not related to post-transplant HRQOL.
The data presented in Figure 2 and in Table IV
summarize the effect of HCV infection on the SF-36
score profile. HCV-negative patients were within
general population norms on six of eight SF-36 scales
post-transplant. HCV positive patients were within
general population norms on four of eight scales post-
transplant; they differed from HCV-patients in this
respect on the bodily pain and social functioning
scales. Discriminant function analysis demonstrated
that the score profiles for HCV and HCV recipi-
ents differed significantly (canonical correlation
0.50, pB0.001). Table IV demonstrates that the
discriminant function correctly classified 73% of cases
(65% after cross-validation; kappa0.46, pB0.001).
Discussion
Increasing emphasis has been placed on assessment
of the impact of liver transplantation on recipients’


















PF RP BP GH VT SF RE MH
SF-36 scales
Pre-Transplant Post-Transplant
US Population Norms +/- SD
Figure 1. Pre- and post-transplant SF-36 score profiles. Shaded bar segments are average pre-transplant scores and unshaded segments the
average post-transplant improvement in each scale. The full height of each bar represents the mean post-transplant score. Univariate tests of
the effect of transplant on these scores demonstrated significant improvement (pB0.001) on all scales after transplant. The line graph
overlay represents the US population norms with error bars demonstrating 91 SD. The pre-transplant profile shows candidates to have
substantively reduced HRQOL on 7 of 8 scales. The post-transplant profile shows recipients to have HRQOL that is within general
population standards on 6 of 8 scales. Abbreviations for scales: PFphysical functioning, RProle physical, BPbodily pain, GH
general health, VTvitality, SFsocial functioning, RErole emotional, MHmental health.
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demonstrated significant improvement on all SF-36
measures and on FP. These findings confirm and also
provide new information regarding factors that affect
HRQOL after liver transplantation [1,2,14,15]. How-
ever, investigation into the effect of specific clinical
covariates on a HRQOL profile after liver transplan-
tation has not been reported.
HCV is the largest single cause of liver disease
leading to cirrhosis and the need for organ transplan-
tation. Half (51%) of our sample underwent liver
transplantation secondary to HCV. For this reason, it
is beneficial to characterize how this diagnosis may
affect post-transplant HRQOL. Several studies have
addressed the effect of HCV and recurrent post-
transplant HCV on overall HRQOL, but no studies
have described the effect of the diagnosis of HCV on
individual post-transplant quality of life scales. Singh
and co-authors compared HRQOL between liver
transplant recipients with recurrent HCV to a group
of recipients without recurrent HCV at different time-
points. Six months after transplantation, both groups
experienced significant improvement in Karnofsky
functional performance scores, but improvement
was less in patients with recurrent HCV. All other
measures of HRQOL at 6 months, including depres-
sive symptoms, mood disturbance, overall perceived
Table III. Multivariate models of post-transplant SF-36 HRQOL.
Component/scale
effect/parameter PCS MCS PF RP BP GH VT SF RE MH
Pre-transplant SF-36
score
0.394** 0.286* 0.195* 0.204* 0.319** 0.274* 0.199* 0.353** 0.172 0.306*
Time post-transplant 0.215* 0.082 0.133 0.303* 0.146 0.084 0.035 0.001 0.074 0.084
FP at transplant 0.022 0.085 0.149 0.050 0.097 00.47 0.012 0.092 0.033 0.041
Hepatitis C (Y/N) 0.119 0.169 0.127 0.232* 0.252* 00.47 0.065 0.162 0.314* 0.139
MELD ]18 0.135 0.052 0.132 0.181* 0.155 0.032 0.099 0.129 0.101 0.103
Any rejection episode 0.150 0.073 0.113 0.077 0.240* 0.099 0.227* 0.143 0.002 0.060
Any infectious episode 0.162 0.002 0.161 0.069 0.153 0.055 0.195 0.113 0.107 0.076
Model p B0.001 0.056 0.024 B0.001 B0.001 0.262 0.098 B0.001 0.020 0.018
Model R2 0.298 0.147 0.151 0.244 0.391 0.091 0.120 0.236 0.164 0.163
Unless noted otherwise, table entries are standardized regression coefficients. **p50.001, *p50.05.
Model R2squared multiple correlation coefficient.
FPKarnofsky functional performance; MELDmodel of end-stage liver disease.
Abbreviations for SF-36 components and scales: PCSphysical component summary, MCSmental component summary, PFphysical
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SF-36 scales
HCV+ HCV-
US Population Norms +/- SD
Figure 2. SF-36 post-transplant score profiles in patients with and without Hepatitis C (HCV and HCV). Shaded bar segments are
average post-transplant scores in HCV recipients, while unshaded segments are average post-transplant differences in HCV recipients.
The total heights of individual bars are mean post-transplant HRQOL scores in HCV recipients. The line graph overlay represents the
US population norms with error bars demonstrating 9SD. HCV recipients had post-transplant scores that were within general
population standards on four of eight SF-36 scales. HCV recipients were within general population standards on six of eight scales.
Abbreviations for scales: PFphysical functioning, RProle physical, BPbodily pain, GHgeneral health, VTvitality, SFsocial
functioning, RErole emotional, MHmental health.
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QOL, and coping scores, improved significantly with-
out differences between the two groups. At one year,
patients with recurrent HCV hepatitis had signifi-
cantly lower functional status, perceived QOL, and
greater depressive symptoms compared to all other
patients combined [16]. Likewise, Feurer and collea-
gues reported the negative effect of recurrent hepatitis
C virus (HCV) infection on the trajectory of func-
tional performance between post-transplant years two
and three in liver transplant recipients. Using a
multivariate model they demonstrated a negative
effect of HCV on functional performance [9]. In our
current report, we assessed whether the diagnosis of
HCV, not post-transplant recurrence, had an effect on
the HRQOL profile. The diagnosis of HCV had a
significant negative effect on SF-36 role physical,
bodily pain, and role emotional domains (Table III).
Patients with HCV not only experience lower
HRQOL in several physical domains, but also in
one mental domain.
The model for end-stage liver disease (MELD)
score is an objective liver disease scoring index that
has replaced the Child Turcott Pugh (CTP) score for
allocation of organs to patients with advanced,
chronic liver disease awaiting orthotopic liver trans-
plantation. The MELD score  calculated from total
serum bilirubin, creatinine, and international normal-
ized ratio (INR)  has been shown to be a reliable and
valid predictor of short-term mortality in patients with
end-stage liver disease [17,18]. Although the MELD
score was originally proposed as a model to predict
short-term mortality in patients with end-stage liver
disease, in clinical practice it is often used as an overall
indicator of the patient’s functional health status.
Several studies have reported associations between
CTP, MELD scores, and HRQOL of patients
with end-stage liver disease with conflicting results
[1923]. In patients awaiting liver transplantation,
Saab and colleagues identified there to be no correla-
tion between MELD score and HRQOL [21]. How-
ever, in the first report examining recipients, Kanwal
and colleagues showed a small to moderate negative
correlation between HRQOL and increasing MELD,
specifically in physical functioning [20]. In keeping
with the previous findings, Rodrigue and colleagues
showed that increasing MELD score was negatively
associated with HRQOL after liver transplantation,
especially as it relates to physical functioning [22].
Recently, Castaldo and colleagues, at our institution,
have shown that recipients with higher pre-transplant
MELD have better post-transplant physical HRQOL,
but that MELD score is not correlated with post-
operative mental HRQOL [23]. Despite the previous
literature on MELD and HRQOL, there are no data
evaluating the effect of MELD on individual HRQOL
domains in a HRQOL profile. From our multivariate
models, a MELD score ]18 has a positive effect on
SF-36 role physical and a marginal effect on bodily
pain. This finding may be a function of self-perceived
and self-reported improvement in HRQOL in com-
parison to their pre-operative status.
Twenty-three percent of our population experi-
enced one or more rejection episodes confirmed by
liver biopsy, consistent with rates reported at other
centers with comparable immunosuppression regi-
mens [24,25]. All patients experiencing rejection
episodes required either an increase/change in their
immunosuppression, pulse-dose steroids, or both.
The additional procedures, inpatient admissions,
more frequent outpatient visits secondary to these
episodes had a negative effect on these patients’
HRQOL. This group had significantly lower scores
on SF-36 bodily pain and vitality scales. Knowledge of
significant effects of rejection on certain HRQOL
domains may enhance providers’ abilities to care for
these patients.
It is also important to recognize that pre-transplant
functional performance measured by Karnofsky
scores had no affect on post-transplant HRQOL.
Pinson and co-authors described the trajectory of
improvement of functional performance for patients
after liver transplantation. Poorly functioning patients
preoperatively reached equal functional performance
plateaus as those patients with high preoperative
functional status by 24 months [2]. Our findings
support these previous findings that preoperative
Table IV. Discriminant analysis classification findings for the effect of SF-36 score profiles on HCV status.
Predicted group membership Total
HCV (y/n) No Yes No
Original Count no 36 13 49
yes 13 34 47
% no 73.5 26.5 100.0
yes 27.7 72.3 100.0
Cross-validated Count no 30 19 49
yes 15 32 47
% no 61.2 38.8 100.0
yes 31.9 68.1 100.0
In cross-validation, each case is classified by the functions derived from all cases other than that case.
73% of original grouped cases correctly classified.
65% of cross-validated grouped cases correctly classified.
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functional performance was not predictive of post-
operative status.
Strengths of this study include its prospective
design, which allowed us to follow a specific popula-
tion and characterize significant changes in QOL,
affective status, and functional performance with a
diverse battery of HRQOL measures. The broad
assessment of HRQOL with well-validated instru-
ments in a relatively large cohort makes it more likely
that findings will generalize to other liver transplant
populations. In addition, the multivariate modeling
delineating positive and negative influences of certain
pre-transplant and post-transplant covariates on a
HRQOL profile helps clinicians recognize these
effects in their liver transplant recipients. Due to our
design requiring that both pre- and post-transplant
data be available for several HRQOL measures, a
limitation of this study is that the cohort that met our
inclusion criteria represents only two-thirds of our
total non-veteran population that was transplanted
over this time period. Responder bias becomes a
concern with any study relying on self-report of QOL
depending on which population chooses to participate
in the QOL evaluations. Despite the fact that our
cohort had a broad range of scores on all HRQOL
instruments prior to and after transplantation, con-
sistent with previous literature [1,2,26,27], the possi-
bility of this bias cannot be completely eliminated.
Overall improvement in mental and physical
HRQOL of life after liver transplantation is well
established. However, the effects of specific clinical
covariates on a HRQOL profile have not been
established and their effects are varied. HCV,
MELD score, and biopsy-confirmed rejection epi-
sodes were influential on one or more HRQOL
outcomes. Post-transplant scores on all SF-36 do-
mains, except role emotional, were related to pre-
transplant scores. Physical HRQOL and role physical
improved with time post-transplant, while the remain-
ing scales showed a sustained improvement that was
not dependent on time post-transplant. Post-trans-
plant infections and pre-transplant functional perfor-
mance were not related to post-transplant HRQOL.
These findings can aid clinicians in recognizing the
varied effects of pre-transplant clinical conditions and
post-transplant clinical events on a physical and
mental HRQOL outcome profile.
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